Reboxetine


Concise Prescribing Info
Indications/Uses
Depression.
Dosage/Direction for Use
Adult : PO 4 mg twice daily, then up to 10 mg/day after 3-4 wk if needed. Max: 12 mg/day.
Dosage Details
Oral
Depression
Adult: 4 mg bid, may increase to 10 mg daily after 3-4 wk if necessary. Max: 12 mg daily.
Elderly: 2 mg bid, may increase dose to 6 mg/day after 3 ww if required.
Renal Impairment
Initiate with lower doses: 2 mg bid; may increase gradually according to tolerance.
Hepatic Impairment
Initiate with lower doses: 2 mg bid; may increase gradually according to tolerance.
Administration
May be taken with or without food.
Special Precautions
Renal and hepatic impairment, benign prostatic hyperplasia, cardiac disorders, epilepsy, bipolar disorders, urinary retention, glaucoma. May impair ability to perform tasks requiring mental alertness, driving or operating machinery. Monitor for signs of clinical worsening eg. suicidal tendency especially during the initial phase of the treatment.
Adverse Reactions
Insomnia, dizziness, increased sweating, impotence, dry mouth, constipation, urinary hesitancy, dry mouth, postural hypotension, dysuria, paraesthesia, hyponatraemia, tachycardia.
Potentially Fatal: Tachycardia.
Drug Interactions
Avoid concomitant admin with antiarrhythmics, antipsychotics, ciclosporin, imidazole and triazole antifungals, TCAs. Concurrent use with CYP3A4 inhibitors may increase plasma levels of reboxetine. Concurrent use with ergot derivatives may increase BP.
Potentially Fatal: Risk of hypertensive crisis when used with MAOIs.
Action
Description: Reboxetine selectively and potently inhibits norepinephrine reuptake. It also has a weak effect on serotonin reuptake.
Pharmacokinetics:
Absorption: Well absorbed; peak plasma concentrations about 2 hr after oral dose.
Distribution: Protein-binding: 97%.
Metabolism: Metabolised by CYP3A4. Dealkylation, hydroxylation, oxidation followed by glucuronide and sulfate conjugations.
Excretion: Mainly via urine (78%) with 10% as unchanged drug; 13 hr (elimination half-life).
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Reboxetine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in